Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
Physiological Reports2021Vol. 9(3), pp. e14721–e14721
Citations Over TimeTop 10% of 2021 papers
Yannick Cyr, Valérie Lamantia, Simon Bissonnette, Mélanie Burnette, Aurèle Besse‐Patin, Annie Demers, Martin Wabitsch, Michel Chrétien, Gaétan Mayer, Jennifer L. Estall, Maya Saleh, May Faraj
Abstract
Normocholesterolemic subjects with lower plasma PCSK9 and higher WAT surface-expression of LDLR and CD36 have higher WAT NLRP3 inflammasome activation and T2D risk factors. This may be due to LDL-induced inhibition of adipocyte function.
Related Papers
- → Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)(2013)231 cited
- → On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects(2014)80 cited
- → A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro(2018)15 cited
- → Development and functional analysis of novel PCSK9/LDLR interaction inhibitors for hypercholesterolemia treatment(2021)
- → Dihydromyricetin promotes LDL metabolism in HepG2 cells through the PCSK9/LDLR pathway(2023)